BIOMARKER:

FGF19 amplification + HRAS Q61R + TP53 672+2T>G

Entrez ID:

7157; 3265; 9965

Related biomarkers:

‹

›

FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	APR-246 Sensitive: D – Preclinical	APR-246 Sensitive: D – Preclinical
FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	MK-2206 Sensitive: D – Preclinical	MK-2206 Sensitive: D – Preclinical
FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	tipifarnib Sensitive: D – Preclinical	tipifarnib Sensitive: D – Preclinical
FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	erdafitinib Sensitive: D – Preclinical	erdafitinib Sensitive: D – Preclinical
FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	INNO-406 Sensitive: D – Preclinical	INNO-406 Sensitive: D – Preclinical
FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer Prostate Cancer	abemaciclib Sensitive: D – Preclinical	abemaciclib Sensitive: D – Preclinical